| Literature DB >> 32066417 |
Peifen Chen1, Jihong Jiang2, Yunhe Zhang3, Guobao Li4, Zhihui Qiu5, Mitchell M Levy6, Baoji Hu7.
Abstract
BACKGROUND: Because of its analgesic and light sedative properties, the highly selective alpha-2 adrenergic receptor agonist dexmedetomidine (DEX) has been suggested for the treatment of septic patients, but its effect on the duration of mechanical ventilation remains unclear. The present study was conducted to review the extant literature in DEX and determine its influence on ventilation time in adult septic patients.Entities:
Keywords: Dexmedetomidine; Duration of mechanical ventilation; Sepsis; Systematic review and meta-analysis
Year: 2020 PMID: 32066417 PMCID: PMC7026965 DOI: 10.1186/s12890-020-1065-6
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Flow diagram of the study retrieved, excluded, assessed and included
Characteristics of the included study and summary of the outcome
| First author (year) | Type of trial | Age (years) | Patients Included | Interventions and dose | sedation levels | Outcome | |
|---|---|---|---|---|---|---|---|
| mechanical ventilation (days) | 28-day mortality (n) | ||||||
| Tasdogan et al, 2009 [ | Single-center Not blind | 19-78 | 40 septic patients 1. 20 in the control group 2. 20 in experimental group | 1. Control: propofol Loading: 1 mg/kg over 15minutes Maintenance: 1-3 mg/kg/hr over a 24 hours 2. Experimental: dexmedetomidine Loading: 1μg/kg over 10minutes Maintenance: 0.2-2.5μg/kg/hr over a 24 hours | Ramsay score < 2 | Duration of mechanical ventilation in survivor (Medians[min-max]) 1. Control: 6 [4-9] 2. Experimental: 7 [5-10] | 1. Control:2 (20) 2. Experimental: 1 (20) |
| Pandharipande et al, 2010 [ | Two-center Double-blind | 44-68 | 63 septic patients 1. 32 in the control group 2. 31 in experimental group | 1. Control: lorazepam Start: 1 mg/hr. Maximum: 10 mg/hr 2. Experimental: dexmedetomidine Started: 0.15 μg /kg/hr. Maximum: 1.5 μg /kg/hr | RASS score 1 | Ventilator-free days (mean standard ± deviation) 1. control: 10.1± 10.3 2. Experimental: 15.2± 10.6 | 1. control : 13 (32) 2. Experimental: 5 (31) |
| Guo, et al, 2016 [ | Single-center No blind | 58.5±19 | 45 septic shock patients 1. 15 in the control group A 2. 16 in the control group B 3. 14 in experimental group | 1. Control A:midazolam 2. Control B: propofol 3. Experimental: dexmedetomidine 0.2-0.7 μg/kg/hr + propofol | RASS score -1 to -2 | Duration of mechanical ventilation (mean standard ±deviation) 1. Control A: 17.7±5.7 2. Control B: 16.9 ±5.7 3. Experimental: 14.2 ±5.7 | 1. Control A: 2 (15) 2. Control B: 2 (16) 3. Experimental: 2 (14) |
| Kawazoe, et al, 2017 [ | Multicenter blinded-endpoint | Control: 69 (13.6) Experimental: 68 (14.9) | 201 septic patients 1. 101 in the control group 2. 100 in experimental group | 1. Control: propofol + midazolam Propofol titrated 0.-3 mg/kg/hr Midazolam titrated 0-0.15 mg/kg/hr 2. Experimental: dexmedetomidine + propofol + midazolam dexmedetomidine started from 0.1 μg /kg/hr, titrated 0.1 – 0.7 μg /kg/hr minimum propofol /midazolam as needed | RASS score Day: 0 Night: -2 | Duration of mechanical ventilation (mean[IQR]) 1.Control: 6 [IQR 3-11] 2. Experimental: 6 [IQR 3-11] Ventilator-free days (mean[IQR]) 1. Control: 18 [IQR 0.5-23] 2. Experimental: 20 [IQR 5-24] | 1. Control: 28 (101) 2. Experimental: 19 (100) |
Fig. 2Risk of bias summary
Fig. 3Risk of bias graph
Summary of findings for the main comparison
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants | Quality of the evidence (GRADE) | |
|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | ||||
| Control | DEX | ||||
Ventilator-free days Follow-up: mean 3.57 days | The mean ventilator-free days in the intervention groups was 3.57 higher (0.26 to 6.89 higher) | 264 (2 studies) | ⊕⊕⊕⊝ moderate1 | ||
Duration of mechanical ventilation Follow-up: mean 0.07 days | The mean duration of mechanical ventilation in the intervention groups was 0.07 higher (1.58 lower to 1.72 higher) | 267 ( 3 studies) | ⊕⊕⊕⊝ moderate2 | ||
| mortality | Study population | RR 0.64 (0.4 to 0.93) | 333 (4 studies) | ⊕⊕⊕⊕ high | |
| 268 per 1000 | 163 per 1000 ( 107 to 249) | ||||
| Moderate | |||||
| 205 per 1000 | 125 per 1000 (82 to 191) | ||||
Fig. 4Comparison of duration of mechanical ventilation between patients in the DEX group and Propofol group
Fig. 5Comparison of duration of mechanical ventilation between patients in the DEX group and Midazolam group
Fig. 6Secondary outcome. DEX was associated with a reduction of ventilator-free days
Fig. 7Secondary outcome. DEX improved short-term mortality
Fig. 8Sensitivity analysis
Fig. 9Funnel plot of the duration of ventilator-free days. The hollow dots and dotted line indicate individual studies and 95% confidence intervals, respectively
Fig. 10Funnel plot of mortality. The hollow dots and dotted line indicate individual studies and 95% confidence intervals, respectively